CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 501–600 of 1,010
Minimal change disease: a “two-hit” podocyte immune disorder?
Shimada, M., Araya, C. E., Rivard, C. J., Ishimoto, T., Johnson, R. J., & Garin, E. H. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1676-x · Cited by 127
“Furthermore, CTLA-4 also suppresses CD80 expression on the antigen-presenting cells [5].”
BackgroundCombination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
“Specific deletion of CTLA-4 in Tregs is sufficient tomaintain aberrant T-cell activation and lead to autoimmunity (53).”
BackgroundTNF-α: An Activator of CD4+FoxP3+TNFR2+ Regulatory T Cells
Chen, X., & Oppenheim, J. J. (2010) · Current directions in autoimmunity · doi:10.1159/000289201 · Cited by 126
Arora, M., Poe, S. L., Oriss, T. B., Krishnamoorthy, N., Yarlagadda, M., Wenzel, S. E., Billiar, T. R., Ray, A., & Ray, P. (2010) · Mucosal Immunology · doi:10.1038/mi.2010.41 · Cited by 126
Yu, P., Steel, J. C., Zhang, M., Morris, J. C., Waitz, R., Fasso, M., Allison, J. P., & Waldmann, T. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203479109 · Cited by 119
“Studies have suggested that CTLA-4 blockade interferes with Treg function and inhibits their ability to suppress T-cell proliferation (32, 33).”
BackgroundImpact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 125
Activated β-catenin in Foxp3+ regulatory T cells links inflammatory environments to autoimmunity
Sumida, T., Lincoln, M. R., Ukeje, C. M., Rodriguez, D. M., Akazawa, H., Noda, T., Naito, A. T., Komuro, I., Dominguez-Villar, M., & Hafler, D. A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0236-6 · Cited by 121
Ohkura, N., Yasumizu, Y., Kitagawa, Y., Tanaka, A., Nakamura, Y., Motooka, D., Nakamura, S., Okada, Y., & Sakaguchi, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.006 · Cited by 104
Self-citationInterleukin-2 and regulatory T cells in rheumatic diseases
Kolios, A. G. A., Tsokos, G. C., & Klatzmann, D. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00707-x · Cited by 127
Molecular signatures of T-cell inhibition in HIV-1 infection
Larsson, M., Shankar, E. M., Che, K. F., Saeidi, A., Ellegård, R., Barathan, M., Velu, V., & Kamarulzaman, A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-31 · Cited by 126
“This negative regulator is constitutively expressed on CD4CD25FoxP3 Tregs, which suppress autoimmunity and maintain peripheral tolerance, whereas other T-cell subsets express this factor only following activation [34,36].”
BackgroundOverexpression of Cytotoxic T-Lymphocyte–Associated Antigen-4 Prevents Atherosclerosis in Mice
Matsumoto, T., Sasaki, N., Yamashita, T., Emoto, T., Kasahara, K., Mizoguchi, T., Hayashi, T., Yodoi, K., Kitano, N., Saito, T., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306848 · Cited by 125
“Downregulation of CD80 and CD86 expression on DCs by CTLA-4 is reported to be a key mechanism for Tregmediated suppression.(13) Therefore, we examined CD80 and CD86 expression on splenic CD11c major histocompatibility complex DCs from Apoe or CTLA-4-Tg/Apoe mice and found a significant decrease in their expression in…”
Self-citationEpigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation
Mikami, N., Kawakami, R., Chen, K. Y., Sugimoto, A., Ohkura, N., & Sakaguchi, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922600117 · Cited by 118
“In addition, assuming that nTregs expressing CTLA-4 are able to down-modulate CD80/CD86 expression by APCs (52), they may help render self-reactive T cells anergic (53) and also contribute to the generation of functionally stable pTregs with Treg-type DNA hypomethylation in a manner of infectious tolerance (54).”
InfluentialSelf-citationQuorum-Sensing in CD4+ T Cell Homeostasis: A Hypothesis and a Model
Almeida, A. R. M., Amado, I. F., Reynolds, J., Berges, J., Lythe, G., Molina-París, C., & Freitas, A. A. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00125 · Cited by 114
“More importantly, recent findings using Treg cells with a specific CTLA-4 deficiency indicate that CTLA-4 is required for Treg cells to suppress immune responses by disrupting the ability of antigen-presenting cells to activate other T cells (Wing et al., 2008).”
BackgroundRegulatory T cells: roles of T cell receptor for their development and function
Ohkura, N., & Sakaguchi, S. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-010-0200-5 · Cited by 124
“Indeed, in the presence of specific antigen, Treg cells outcompete with naïve T cells in forming aggregates around antigen-presenting DCs [25, 29].”
BackgroundInfluentialSelf-citationThe effect of ionizing radiation on regulatory T cells in health and disease
Persa, E., Balogh, A., Sáfrány, G., & Lumniczky, K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.003 · Cited by 123
Li, Z., Lin, F., Zhuo, C., Deng, G., Chen, Z., Yin, S., Gao, Z., Piccioni, M., Tsun, A., Cai, S., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586651 · Cited by 110
Thymic Versus Induced Regulatory T Cells – Who Regulates the Regulators?
Povoleri, G. A. M., Scottà, C., Nova‐Lamperti, E., John, S., Lombardi, G., & Afzali, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00169 · Cited by 125
“…of Tregs, therefore,a number of additional markers have been proposed as Treg-specifying, including cytotoxic T-lymphocyte antigen-4 (CTLA-4) (Wing et al., 2008; Sakaguchi et al., 2009), GITR (glucocorticoid-induced TNF receptor family related protein; TNFRSF18) (Shimizu et al., 2002), CD39…”
BackgroundInfluentialRegulatory T Cells in Allergy and Asthma
Martín‐Orozco, E., Norte‐Muñoz, M., & Martínez-García, J. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00117 · Cited by 123
“IL-10 has immunosuppressive functions and can modulate the activity of several cell subsets involved in allergic reactions, such as mast cells (216), Th2 T cells (217), eosinophils, and DCs (149).”
BackgroundInfluentialIL-33–mediated IL-13 secretion by ST2+ Tregs controls inflammation after lung injury
Liu, Q., Dwyer, G. K., Zhao, Y., Li, H., Mathews, L. R., Chakka, A. B., Chandran, U. R., Demetris, J. A., Alcorn, J. F., Robinson, K. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123919 · Cited by 122
CTLA‐4 is required by CD4+CD25+ Treg to control CD4+ T‐cell lymphopenia‐induced proliferation
Sojka, D. K., Hughson, A., & Fowell, D. J. (2009) · European Journal of Immunology · doi:10.1002/eji.200838603 · Cited by 103
Schönfeld, D. L., Matschiner, G., Chatwell, L., Trentmann, S. M., Gille, H., Hülsmeyer, M., Brown, N., Kaye, P. M., Schlehuber, S., Hohlbaum, A. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813399106 · Cited by 124
“The cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152) is a critical T cell regulatory molecule (8, 9) that has attracted attention as a target for immunotherapy of cancer (10, 11) as well as HIV (12) and other infectious diseases (13, 14).”
BackgroundAnnexin A1 as a Regulator of Immune Response in Cancer
Araújo, T. G., Mota, S. T. S., Ferreira, H. S. V., Ribeiro, M. A., Goulart, L. R., & Vecchi, L. (2021) · Cells · doi:10.3390/cells10092245 · Cited by 121
“Activation of T cells is additionally compromised by the downregulation of co-stimulatory molecules on DCs mediated by Tregs [76].”
BackgroundComprehensive analysis of current approaches to inhibit regulatory T cells in cancer
Pere, H., Tanchot, C., Bayry, J., Terme, M., Taieb, J., Badoual, C., Adotevi, O., Merillon, N., Marcheteau, E., Quillien, V., et al. (2012) · OncoImmunology · doi:10.4161/onci.18852 · Cited by 104
“Adenosine is a major immunosuppressive factor that may participate in the immunosuppressive activity of Foxp3 T cells.(16) Low molecular weight inhibitors and adenosine receptor antagonists, some of which are already used in clinic settings for other indications, are available to block adenosine-mediated immune suppre…”
BackgroundT Regulatory Cells Support Plasma Cell Populations in the Bone Marrow
Glatman Zaretsky, A., Konradt, C., Dépis, F., Wing, J. B., Goenka, R., Atria, D. G., Silver, J. S., Cho, S., Wolf, A. I., Quinn, W. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.067 · Cited by 106
“Next, we analyzed mice with a Treg cell-specific loss of CTLA-4 expression (Foxp3/ CTLA4), which develop systemic inflammation (Wing et al., 2008).”
BackgroundMethodSelf-citationRegulatory T Cells in Systemic Sclerosis
Frantz, C., Auffray, C., Avouac, J., & Allanore, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02356 · Cited by 122
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Abdoli Shadbad, M., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 107
“Lack of CTLA4 in Tregs is the cause of T-cell activation and autoimmunity [39,40].”
BackgroundHaque, A., Best, S. E., Amante, F. H., Mustafah, S., Desbarrieres, L., Rivera, F. D. L., Sparwasser, T. D., Hill, G. R., & Engwerda, C. R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001221 · Cited by 119
Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo
Ulges, A., Klein, M., Reuter, S., Gerlitzki, B., Hoffmann, M., Grebe, N., Staudt, V., Stergiou, N., Bohn, T., Brühl, T.-J., et al. (2015) · Nature Immunology · doi:10.1038/ni.3083 · Cited by 119
Control of Germinal Center Responses by T-Follicular Regulatory Cells
Wing, J. B., Tekgüç, M., & Sakaguchi, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01910 · Cited by 120
Self-citationTCF1 and LEF1 Control Treg Competitive Survival and Tfr Development to Prevent Autoimmune Diseases
Yang, B.-H., Wang, K., Wan, S., Liang, Y., Yuan, X., Dong, Y., Cho, S., Xu, W., Jepsen, K., Feng, G.-S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.061 · Cited by 113
“CTLA4 is a critical functional molecule for Treg’s suppressive function via inhibiting DC maturation (Wing et al., 2008).”
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 121
“In addition, CTLA4 expressed by T reg cells outcompetes CD28 for binding to CD80 and CD86 on APCs 234 , resulting in suppression of APC functions.”
Immune checkpoints in central nervous system autoimmunity
Joller, N., Peters, A., Anderson, A. C., & Kuchroo, V. K. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01136.x · Cited by 106
“Furthermore, CTLA-4 is instrumental in reducing the level of costimulatory B7 molecules on APCs, as the observed reduction of CD80 and CD86 on APCs conditioned by Tregs is abrogated in the presence of CTLA-4 blocking antibody or when CTLA-4 KO Tregs are used (19, 126, 127).”
BackgroundLin, Y., Mahalingam, J., Chiang, J., Su, P., Chu, Y., Lai, H., Fang, J., Huang, C., Chiu, C., & Lin, C. (2013) · International Journal of Cancer · doi:10.1002/ijc.27784 · Cited by 112
T cells in pancreatic cancer stroma
Goulart, M. R., Stasinos, K., Fincham, R. E. A., Delvecchio, F. R., & Kocher, H. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i46.7956 · Cited by 119
Kelada, S. N. P., Sethupathy, P., Okoye, I., Kistasis, E., Czieso, S., White, S., Chou, D. B., Martens, C., Ricklefs, S., Virtaneva, K. I., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003451 · Cited by 120
“at environmental interfaces [2] and internal organs [3], preventing”
BackgroundLi, B., Jin, J., Guo, D., Tao, Z., & Hu, X. (2023) · Cancers · doi:10.3390/cancers15102858 · Cited by 117
Yamaguchi, T., Kishi, A., Osaki, M., Morikawa, H., Prieto-Martin, P., Wing, K., Saito, T., & Sakaguchi, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307185110 · Cited by 109
“Treg-specific CTLA-4 deficiency produces fatal autoimmune/ inflammatory disease via impairment of Treg suppressive activity (12).”
BackgroundMethodSelf-citationTraxinger, B. R., Richert-Spuhler, L. E., & Lund, J. M. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00471-x · Cited by 118
T follicular regulatory (Tfr) cells: Dissecting the complexity of Tfr‐cell compartments
Fonseca, V. R., Ribeiro, F., & Graça, L. (2019) · Immunological Reviews · doi:10.1111/imr.12739 · Cited by 115
Halvorsen, E. C., Hamilton, M. J., Young, A., Wadsworth, B. J., LePard, N. E., Lee, H. N., Firmino, N. S., Collier, J. L., & Bennewith, K. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1150398 · Cited by 116
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 116
“Importantly blockade of galectin-9 on Tregs by “masking” with glucose or smallinterfering RNA knockdown averted the suppression of CD8+ T cells restricted by these non-protective HLA alleles.”
BackgroundInfluentialRevilla, S. A., Kranenburg, O., & Coffer, P. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903564 · Cited by 116
Haseda, F., Imagawa, A., Murase‐Mishiba, Y., Terasaki, J., & Hanafusa, T. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12116 · Cited by 290
Regulatory T cells: immune suppression and beyond
Wan, Y. Y. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.20 · Cited by 114
Regulatory T Cells and Atherosclerosis
Lopez‐Pastrana, J., 沙晓津, Virtue, A., Mai, J., Cueto, R., Lee, I. A., Wang, H., & Yang, X.-F. (2013) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.s12-002 · Cited by 114
Pletinckx, K., Döhler, A., Pavlović, V., & Lutz, M. B. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00039 · Cited by 114
“Unlike CD28 costimulation the interaction between CD80/CD86 molecules on DCs and CTLA-4 on T cells initially does not seem to play a role in the development of Tregs, since CTLA-4−/− mice exhibit normal numbers of Foxp3+ T cells (Tang et al., 2004; Kataoka et al., 2005; Wing et al., 2008).”
Targeting immune checkpoints in hematological malignancies
Salik, B., Smyth, M. J., & Nakamura, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00947-6 · Cited by 113
Clinical perspectives for regulatory T cells in transplantation tolerance
Hippen, K. L., Riley, J. L., June, C. H., & Blazar, B. R. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.008 · Cited by 113
“HLA-DR+, Lag-3+, CD45RA, CTLA-4)[51-54], although the cGMP purification reagents for these markers are not yet available, and whether they remain more potent after expansion will have to be determined.”
BackgroundCombinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 105
“critical for inhibitory function of Tregs [4].”
Moy, J. D., Moskovitz, J. M., & Ferris, R. L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.035 · Cited by 115
“Although the transient expression of CTLA4 on CD8+ T cells regulates effector/memory activity [63–65], the inhibitory function of CTLA4appears to be more importantonCD4+ Tregs, where CTLA4 is constitutively expressed at high levels [66,67].”
BackgroundIntrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity
Atretkhany, K. N., Mufazalov, I. A., Dunst, J., Kuchmiy, A. A., Gogoleva, V. S., Andruszewski, D., Drutskaya, M. S., Faustman, D. L., Schwabenland, M., Prinz, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807499115 · Cited by 113
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
Arumugakani, G., Wood, P. M. D., & Carter, C. R. D. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9351-3 · Cited by 113
“It has recently been suggested from murine and in vitro experiments using human cells that CTLA4 is essential for Foxp3-mediated immunosuppression [26–28].”
BackgroundGut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
Dias, S., D’Amico, A., Cretney, E., Liao, Y., Tellier, J., Bruggeman, C. W., Almeida, F. F., Leahy, J., Belz, G. T., Smyth, G. K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.017 · Cited by 114
“2]) showed that Myb-deficient Treg cells were deficient in CTLA4 (Figure 5D), known to be essential for the suppressive capacity of Treg cells in vivo (Wing et al., 2008).”
BackgroundHou, T. Z., Verma, N., Wanders, J., Kennedy, A., Soskic, B., Janman, D., Halliday, N., Rowshanravan, B., Worth, A. J. J., Qasim, W., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745174 · Cited by 112
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
Corse, E., & Allison, J. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200695 · Cited by 97
“Although these studies (17, 20, 21) showed that interaction with effector T cells could modulate B7 levels on APCs, effects were more dramatic with Tregs, consistent with their higher surface CTLA-4 expression.”
InfluentialKieback, E., Hilgenberg, E., Stervbo, U., Lampropoulou, V., Shen, P., Bunse, M., Jaimes, Y., Boudinot, P., Radbruch, A., Klemm, U., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.018 · Cited by 111
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.008 · Cited by 106
Santegoets, S. J., Stam, A. G., Lougheed, S. M., Gall, H., Jooss, K., Sacks, N., Hege, K., Lowy, I., Scheper, R. J., Gerritsen, W. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0031-3 · Cited by 108
“Alternatively, or additionally, ipilimumab may have altered DC activation state through blocking CTLA-4/B7 interactions at the Treg/DC interface or by direct binding of CTLA-4 on DC [30-32].”
BackgroundT Regulatory Cells in Bone Remodelling
Bozec, A., & Zaiss, M. M. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0356-1 · Cited by 110
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
van Gulijk, M., van Krimpen, A., Schetters, S., Eterman, M., van Elsas, M., Mankor, J., Klaase, L., de Bruijn, M., van Nimwegen, M., van Tienhoven, T., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abn6173 · Cited by 110
Regulatory T cells: stability revisited
Bailey-Bucktrout, S. L., & Bluestone, J. A. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.002 · Cited by 104
Paulsen, E., Kilvaer, T. K., Rakaee, M., Richardsen, E. H., Hald, S. M., Andersen, S., Busund, L., Bremnes, R. M., & Dønnem, T. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2039-2 · Cited by 111
“While naïve T cells upregulate CTLA-4 only after activation, regulatory T cells constitutively express CTLA-4, and the result of CTLA-4 ligation is mediation of the suppressive function of regulatory T cells and inhibition of conventional T cells, but the exact molecular mechanisms remain to be elucidated [11, 12].”
BackgroundImmunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
“The CTLA-4 on Treg causes the attenuation of APC function indirectly by emitting a reverse signal to CD80 and CD86 or effector T cell function, directly [14].”
BackgroundDevi-Marulkar, P., Fastenackels, S., Karapentiantz, P., Goc, J., Germain, C., Kaplon, H., Knockaert, S., Olive, D., Panouillot, M., Validire, P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04356-y · Cited by 112
Regulatory T Cell DNA Methyltransferase Inhibition Accelerates Resolution of Lung Inflammation
Singer, B. D., Mock, J. R., Aggarwal, N. R., Garibaldi, B. T., Sidhaye, V. K., Florez, M. A., Chau, E. P., Gibbs, K. W., Mandke, P., Tripathi, A., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0327oc · Cited by 111
Wang, D., Zhou, R., Yao, Y.-M., Zhu, X.-M., Yin, Y., Zhao, G., Dong, N., & Sheng, Z.-Y. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169961 · Cited by 110
“Among them, CTLA-4 signaling is crucial for CD4 CD25 Tregs to execute their suppressive function (Wing et al., 2008; Schmidt et al., 2009).”
Kondo, Y., Yokosawa, M., Kaneko, S., Furuyama, K., Segawa, S., Tsuboi, H., Matsumoto, I., & Sumida, T. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40398 · Cited by 110
“Pivotal roles of T helper and Treg cells in the pathogenesis of RA and experimentally induced arthritis The importance of CD4+ Tcells in the pathogenesis of RA has been demonstrated in some studies, including investigations on the infiltration of T cells in inflammatory synovial tissue, the association of HLA genes wi…”
BackgroundKonopacki, C., Pritykin, Y., Rubtsov, Y., Leslie, C. S., & Rudensky, A. Y. (2019) · Nature Immunology · doi:10.1038/s41590-018-0291-z · Cited by 101
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 111
“Therefore, blocking CTLA4 by specific monoclonal Abs, such as ipilimumab, not only upregulates helper T-cell functions but also contributes to reducing the immunosuppression mediated by Tregs in the TME [20].”
BackgroundTargeting Costimulatory Molecules to Improve Antitumor Immunity
Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/926321 · Cited by 98
Regulatory T Cells Selectively Control CD8+ T Cell Effector Pool Size via IL-2 Restriction
Kastenmüller, W., Gasteiger, G., Subramanian, N., Sparwasser, T. D., Busch, D. H., Belkaid, Y., Drexler, I., & Germain, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101649 · Cited by 109
“The central importance of CTLA-4 expression on Treg and its function to reduce CD80/CD86 from DC via transendocytosis have recently been demonstrated in vivo (5, 52).”
BackgroundJiang, T. T., Chaturvedi, V., Ertelt, J. M., Kinder, J. M., Clark, D. R., Valent, A. M., Xin, L., & Way, S. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400498 · Cited by 110
“For example, although Treg-intrinsic CTLA-4 is essential for averting systemic autoimmunity (91), targeted deletion of this molecule in Foxp3 cells throughout development in mice does not recapitulate the more rapid onset of fatal disease observed when Tregs are completely lacking.”
BackgroundA second chance for telomerase reverse transcriptase in anticancer immunotherapy
Zanetti, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.67 · Cited by 109
Historical Overview of Immunological Tolerance
Schwartz, R. H. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006908 · Cited by 110
“When the cells emerge into the peripheral circulation, they have an activated phenotype and express molecules such as CTLA-4 and TNFRSF18 (GITR), as well as CD25, which play a role in their function (Itoh et al. 1999; Wing et al. 2008).”
BackgroundArruda, L. C. M., Lorenzi, J. C. C., Sousa, A. P. A., Zanette, D. L., Palma, P. V. B., Panepucci, R. A., Brum, D. G., Barreira, A. A., Covas, D. T., Simões, B. P., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.277 · Cited by 109
Cardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 108
Jacobse, J., Li, J., Rings, E. H. H. M., Samsom, J. N., & Goettel, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716499 · Cited by 109
Human CD8 + Regulatory T Cells Inhibit GVHD and Preserve General Immunity in Humanized Mice
Zheng, J. H., Liu, Y., Liu, Y., Liu, M., Xiang, Z., Lam, K.-T., Lewis, D. B., Lau, Y., & Tu, W. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004943 · Cited by 108
Pastille, E., Bardini, K., Fleissner, D., Adamczyk, A., Frede, A., Wadwa, M., von Smolinski, D., Kasper, S., Sparwasser, T., Gruber, A. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3065 · Cited by 101
Self-citationRegulatory T Helper Cells in Pregnancy and their Roles in Systemic versus Local Immune Tolerance
Ernerudh, J., Berg, G. E., & Mjösberg, J. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2011.01049.x · Cited by 110
Park, K., Park, M.-J., Cho, M., Kwok, S., Ju, J. H., Ko, H.-J., Park, S., & Kim, H. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0210-0 · Cited by 110
The importance of regulatory T‐cell heterogeneity in maintaining self‐tolerance
Yuan, X., Cheng, G., & Malek, T. R. (2014) · Immunological Reviews · doi:10.1111/imr.12163 · Cited by 109
“Mice engineered to contain Tregs that do not express CTLA4 exhibited severe and lethal autoimmunity, even though Treg development and peripheral numbers were normal (79).”
BackgroundFrancis, D. M., & Thomas, S. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.011 · Cited by 107
“CTLA-4 also drives the suppressive function of regulatory T cells [21,22], which can locally inhibit anti-tumor immunity through their accumulation within the tumor microenvironment.”
BackgroundKim, H. R., Park, H. J., Son, J., Lee, J. G., Chung, K. Y., Cho, N. H., Shim, H. S., Park, S., Kim, G., Yoon, H. I., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0785-8 · Cited by 107
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Babamohamadi, M., Mohammadi, N., Faryadi, E., Haddadi, M., Merati, A., Ghobadinezhad, F., Amirian, R., Izadi, Z., & Hadjati, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06391-x · Cited by 107
Yu, G. P., Chiang, D. S., Song, S. J., Hoyte, E. G., Huang, J. J., Vanishsarn, C., & Nadeau, K. C. (2009) · Clinical Immunology · doi:10.1016/j.clim.2008.12.006 · Cited by 108
“GITR (glucocorticoid-induced TNF receptor) and CTLA-4 have been shown to be important for modulating Treg cell function [33-35].”
BackgroundKinsey, G. R., Sharma, R., & Okusa, M. D. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050502 · Cited by 93
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
Xu, W., Liu, K., Chen, M., Sun, J., McCaughan, G. W., Lu, X., & Ji, J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919862692 · Cited by 107
Alissafi, T., Hatzioannou, A., Legaki, A. I., Varveri, A., & Verginis, P. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102310 · Cited by 107
Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle
Hatzioannou, A., Boumpas, A., Papadopoulou, M., Papafragkos, I., Varveri, A., Alissafi, T., & Verginis, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731947 · Cited by 108
Miyara, M., Wing, K., & Sakaguchi, S. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.001 · Cited by 106
Self-citationTumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis
Schatton, T., Scolyer, R. A., Thompson, J. F., & Mihm, M. C. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_16 · Cited by 107
Presicce, P., Orsborn, K. I., King, E. C., Pratt, J. M., Fichtenbaum, C. J., & Chougnet, C. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028118 · Cited by 106
“CTLA-4 is an essential mediator of Treg function, as shown in mice lacking CTLA-4 specifically in Tregs [22].”
BackgroundImmunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 107
“Although CTLA-4 is expressed on activated CD8 T cells, physiologically it may be capable of provoking Treg cells, leading to abolishing the function of T helper cells [18][21,22].”
BackgroundWang, X., Dong, Q., Li, Q., Li, Y., Zhao, D., Sun, J., Fu, J., Meng, F., Lin, H., Luan, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.021 · Cited by 105
Rosenbaum, M., Gewies, A., Pechloff, K., Heuser-Loy, C., Engleitner, T., Gehring, T., Hartjes, L., Krebs, S., Krappmann, D., Kriegsmann, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10203-2 · Cited by 105
Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment
Shen, L., Zhou, Y., He, H., Chen, W., Lenahan, C., Li, X., Deng, Y., Shao, A., & Huang, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8865791 · Cited by 105
“There are various mechanisms of Treg-mediated immune suppression: (a) production of inhibitory cytokines, such as IL-10 and TGF-β [61]; (b) direct killing of effector T cells using perforin and granzyme [62]; (c) dominant consumption of IL-2 through high-affinity CD25[63]; and (d) expression of negative costimulatory…”
BackgroundCortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 105
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.